Evidence map›Paper›PMID 33615175›Full record

ArticleACS pharmacology & translational science2021

Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.

Herana Kamal Seneviratne, Allyson N Hamlin, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Irene Kuo, Mina C Hosseinipour, Ravindre Panchia, Leslie Cottle and 9 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in ACS pharmacology & translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 3 countries.

Herana Kamal SeneviratneDepartment of Medicine, Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Allyson N HamlinDepartment of Medicine, Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Sue LiStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.
Beatriz GrinsztejnEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.
Halima DawoodCentre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban 4041, South Africa.
Albert Y LiuBridge HIV, Population Health Division, San Francisco Department of Health, San Francisco, California 94102, United States.
Irene KuoDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia 20052, United States.
Mina C HosseinipourUNC Project-Malawi, Lilongwe, Malawi.
Ravindre PanchiaPerinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto 1864, South Africa.
Leslie CottleStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.
Gordon ChauStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.
Adeola AdeyeyeDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, United States.
Alex R RinehartViiV Healthcare, Durham, North Carolina 27709, United States.
Marybeth McCauleyFHI360, Durham, North Carolina 27701, United States.
Joseph S EronUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Myron S CohenUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Raphael J LandovitzUCLA Center for Clinical AIDS Research and Education, Los Angeles, California 90035, United States.
Craig W HendrixDepartment of Medicine, Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Namandjé N BumpusDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Johns Hopkins University · USFred Hutch Cancer Center · USUniversity of North Carolina at Chapel Hill · USAPLA Health · USCentre for the AIDS Programme of Research in South Africa · ZAChris Hani Baragwanath Hospital · ZAFamily Health International 360 · USFundação Oswaldo Cruz · BRMilken Institute · USNational Institutes of Health · USSan Francisco Department of Public Health · US

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)U01AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI GRINSZTEJN, BEATRIZ · 2008 to 2011
$14.0M
NIAID NIH HHS U01 AI068613NIAID NIH HHS U01 AI069476NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

Cabotegravir (CAB) is an integrase strand-transfer inhibitor of HIV that has proven effective for HIV treatment and prevention in a long-acting injectable formulation, typically preceded by an oral formulation lead-in phase. Previous

Identifiers

PMID33615175
PMCPMC7888308
OpenAlexW3125711699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.